GoodRx Announces Lowest Discounted Cash Price at Retail Pharmacy Locations for neffy® (epinephrine nasal spray)
26 Septembre 2024 - 3:00PM
Business Wire
neffy is available in pharmacies this
week and the lowest discounted cash price at retail pharmacies can
be found exclusively at GoodRx
neffy is the first and only needle-free
treatment for Type I allergic reactions, including anaphylaxis for
adults and children who weigh ≥30 kg (66 lbs.)
GoodRx (Nasdaq: GDRX), the leading prescription savings platform
in the U.S., today announced it is working with ARS
Pharmaceuticals, Inc. (“ARS Pharmaceuticals”) to offer the lowest
discounted cash price for neffy® in retail pharmacy
locations. Available for purchase in-store this week, consumers who
have been prescribed neffy can now access a pack of two
single-use neffy devices for $199 at more than 70,000
pharmacies nationwide exclusively through GoodRx.
Approved by the Food and Drug Administration in August,
neffy is the first needle-free treatment for Type I allergic
reactions, including anaphylaxis, offering an innovative
alternative to auto-injectors. Unlike traditional methods,
neffy delivers epinephrine nasally, avoiding needle
injections.
"At GoodRx, we’re not just motivated by making essential
medications more accessible and affordable, but also by championing
innovation within well-established markets," said Dorothy Gemmell,
Chief Commercial Officer at GoodRx. “We’re committed to offering
neffy at a lower price so we can help break down
long-standing barriers in anaphylaxis treatment and offer an option
that millions of people, especially children and adults who need to
carry epinephrine, can use to receive timely and effective
treatment.”
Allergies and allergy symptoms impact over 100 million Americans
annually, with more than 50 million experiencing an allergic
reaction each year, underscoring the critical need for accessible
treatment. Anaphylaxis, a severe allergic reaction involving the
whole body, can induce symptoms such as difficulty breathing, fast
heartbeat, hives, nausea, and in severe cases, loss of
consciousness, often occurring within seconds or minutes of
exposure to an allergen. neffy provides a much-needed option
that enhances accessibility and affordability for millions of
Americans.
“We’re thrilled about neffy’s U.S. Food and Drug
Administration approval, so people with severe allergies don’t have
to endure needle-injection of epinephrine, which can be fraught
with anxiety and fear, and can carry a device that’s small and
effective. Through our partnership with GoodRx, we can offer our
innovation in retail pharmacies along with patient programs to
support its affordability,” said Richard Lowenthal, Co-Founder,
President, and Chief Executive Officer of ARS Pharmaceuticals.
"We’re grateful that GoodRx’s platform has helped us reach more
patients and caregivers to access a needle-free option so they can
respond swiftly during a Type 1 allergic reaction.”
By partnering with nearly 150 brands across pharmaceutical
manufacturers, medical device companies, and OTC medicines, GoodRx
directly links savings and patient support programs to high-intent
audiences through its platform, enhancing access to more
cost-effective treatments across the healthcare industry. The
company recently announced an affordability program with Boehringer
Ingelheim to provide its Humira® biosimilar (adalimumab) at a low
cash price available exclusively on GoodRx. Similarly, the company
has partnered with Sanofi to offer its insulin Lantus at just
$35.
Consumers can access the savings on neffy at
www.goodrx.com/neffy
For Important Safety Information, please see
neffy.com and full Patient Information
About GoodRx
GoodRx is the leading prescription savings platform in the U.S.
Trusted by more than 25 million consumers and 750,000 healthcare
professionals annually, GoodRx provides access to savings and
affordability options for generic and brand-name medications at
more than 70,000 pharmacies nationwide, as well as comprehensive
healthcare research and information. Since 2011, GoodRx has helped
consumers save over $75 billion on the cost of their
prescriptions.
GoodRx periodically posts information that may be important to
investors on its investor relations website at
https://investors.goodrx.com. We intend to use our website as a
means of disclosing material nonpublic information and for
complying with our disclosure obligations under Regulation FD.
Accordingly, investors and potential investors are encouraged to
consult GoodRx’s website regularly for important information, in
addition to following GoodRx’s press releases, filings with the
Securities and Exchange Commission (the “SEC”) and public
conference calls and webcasts. The information contained on, or
that may be accessed through, GoodRx’s website is not incorporated
by reference into, and is not a part of, this press release.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements contained in this press release that do not
relate to matters of historical fact should be considered
forward-looking statements, including, without limitation,
statements regarding anticipated consumer savings and
accessibility; the expected benefits and value of our partnership
with ARS Pharmaceuticals and GoodRx’s other offerings; and our
plans, expectations and objectives. These statements are neither
promises nor guarantees, but involve known and unknown risks,
uncertainties and other important factors that may cause our actual
results, performance or achievements to be materially different
from any future results, performance or achievements expressed or
implied by the forward-looking statements, including, but not
limited to, risks relating to our ability to achieve broad market
education and change consumer purchasing habits; changes in
medication pricing and pricing structures; our reliance on a
limited number of industry participants; and the important factors
discussed under the caption “Risk Factors” in our Annual Report on
Form 10-K for the year ended December 31, 2023, and our other
filings with the SEC. Any such forward-looking statements are based
on current expectations, projections and estimates as of the date
of this press release. While we may elect to update such
forward-looking statements at some point in the future, we disclaim
any obligation to do so, even if subsequent events cause our views
to change.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240926822763/en/
press@goodrx.com
GoodRx (NASDAQ:GDRX)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
GoodRx (NASDAQ:GDRX)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024